New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: AstraZeneca | COVID-19 | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Health | Study